UGISense

The company is focusing on novel cancer therapeutics. Its proprietary antisense technology enables the targeting of various tumor types, including cancer stem cells.

UGISense AG was founded in 2016 by Birgit Werner and Thomas Lindhorst, two experienced chemists and entrepreneurs working in biotech for more than 20 years.

The intellectual property of the technology platform is long-term protected; new intellectual property is generated for each new product developed.

UGISense is financed by private investors, Lead Discover Center Dortmund and SeedCapital II Dortmund.